| Schedule of continued operations by reportable segment |
The following tables summarize, for the periods indicated, operating results, from continuing operations by reportable segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended September 30, 2019
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
9,492
|
|
$
|
280
|
|
$
|
9,772
|
|
Direct cost of goods
|
|
|
(2,702)
|
|
|
—
|
|
|
(2,702)
|
|
Sales and marketing costs
|
|
|
(4,370)
|
|
|
—
|
|
|
(4,370)
|
|
Research and development(1)
|
|
|
—
|
|
|
(15,271)
|
|
|
(15,271)
|
|
General and administrative
|
|
|
(669)
|
|
|
(9,300)
|
|
|
(9,969)
|
|
Segment income (loss) from operations
|
|
$
|
1,751
|
|
$
|
(24,291)
|
|
$
|
(22,540)
|
|
Segment assets
|
|
$
|
18,697
|
|
$
|
202,891
|
|
$
|
221,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended September 30, 2018
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
5,168
|
|
$
|
5
|
|
$
|
5,173
|
|
Direct cost of goods
|
|
|
(1,406)
|
|
|
—
|
|
$
|
(1,406)
|
|
Sales and marketing costs
|
|
|
(2,754)
|
|
|
—
|
|
$
|
(2,754)
|
|
Research and development(1)
|
|
|
—
|
|
|
(19,788)
|
|
$
|
(19,788)
|
|
General and administrative
|
|
|
(505)
|
|
|
(8,925)
|
|
$
|
(9,430)
|
|
Segment income (loss) from operations
|
|
$
|
503
|
|
$
|
(28,708)
|
|
$
|
(28,205)
|
|
Segment assets
|
|
$
|
10,765
|
|
$
|
157,781
|
|
$
|
168,546
|
|
Assets held for sale
|
|
|
|
|
|
|
|
|
56,373
|
|
Total consolidated
|
|
|
|
|
|
|
|
$
|
224,919
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
|
|
Products
|
|
Product
|
|
|
|
|
Nine Months Ended September 30, 2019
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
23,816
|
|
$
|
1,683
|
|
$
|
25,499
|
|
Direct cost of goods
|
|
|
(6,972)
|
|
|
—
|
|
|
(6,972)
|
|
Sales and marketing costs
|
|
|
(12,064)
|
|
|
—
|
|
|
(12,064)
|
|
Research and development(1)
|
|
|
—
|
|
|
(57,705)
|
|
|
(57,705)
|
|
General and administrative
|
|
|
(1,808)
|
|
|
(27,388)
|
|
|
(29,196)
|
|
Segment income (loss) from operations
|
|
$
|
2,972
|
|
$
|
(83,410)
|
|
$
|
(80,438)
|
|
Segment assets
|
|
$
|
18,697
|
|
$
|
202,891
|
|
$
|
221,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
|
|
Products
|
|
Product
|
|
|
|
|
Nine Months Ended September 30, 2018
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
17,366
|
|
$
|
525
|
|
$
|
17,891
|
|
Direct cost of goods
|
|
|
(4,546)
|
|
|
—
|
|
$
|
(4,546)
|
|
Sales and marketing costs
|
|
|
(8,443)
|
|
|
—
|
|
$
|
(8,443)
|
|
Research and development(1)
|
|
|
—
|
|
|
(62,332)
|
|
$
|
(62,332)
|
|
General and administrative
|
|
|
(1,270)
|
|
|
(29,075)
|
|
$
|
(30,345)
|
|
Segment income (loss) from operations
|
|
$
|
3,107
|
|
$
|
(90,882)
|
|
$
|
(87,775)
|
|
Segment assets
|
|
$
|
10,765
|
|
$
|
157,781
|
|
$
|
168,546
|
|
Assets held for sale
|
|
|
|
|
|
|
|
|
56,373
|
|
Total consolidated
|
|
|
|
|
|
|
|
$
|
224,919
|
Note 1: Research and development includes the cost of licenses acquired.
|